Comparison between MR Perfusion and 18F-FDG PET in Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing Tissue

Document Type : Research Articles


1 Yale New Haven Health at Bridgeport Hospital, Department of Radiology, 267 Grant Street, Bridgeport, CT, USA

2 St. Vincent's Medical Center , Department of Radiology, 2800 Main Street, Bridgeport, CT, USA

3 SUNY Upstate Medical University, Syracuse NY, USA

4 SUNY Upstate Medical University, Department of Radiology, 750 East Adams Street, Syracuse, NY 13210, USA


Objective: Comparison of the accuracy of MR perfusion and 18-FDG-PET for differentiating tumor progression from nonneoplastic contrast-enhancing tissue. Methods and Materials: Retrospective review of MR perfusion and 18-FDG-PET in 23 cases of primary brain tumors (17 high grade and 6 low grade glial neoplasms) and 5 cases of metastatic lesions with enhancing lesions on post-treatment MRI was performed. The accuracy of MR perfusion versus 18-FDG-PET for distinguishing between nonneoplastic contrast-enhancing tissue and tumor recurrence was assessed. Results: Both CBV (p<0.004) and SUV (p<0.02) are higher in recurrent tumors than necrosis. MR perfusion has an accuracy of 94.5% for differentiating between tumor recurrence and necrosis, while 18-FDG-PET has an accuracy of 85.1% for differentiating between tumor recurrence and nonneoplastic contrast-enhancing tissue. Conclusion: Overall, recurrent tumor demonstrates significantly higher CBV and SUV than nonneoplastic contrast-enhancing tissue. However, MR perfusion appears to be more accurate than FDG PET for distinguishing the two entities.


Main Subjects